Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6551 to 6600 of 8915 results

  1. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    Discontinued Reference number: GID-TA10996

    Technology appraisal guidance
    Discontinued

  3. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    Discontinued Reference number: GID-TA10995

    Technology appraisal guidance
    Discontinued

  4. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  5. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued Reference number: GID-TAG300

    Technology appraisal guidance
    Discontinued

  6. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued Reference number: GID-TAG320

    Technology appraisal guidance
    Discontinued

  7. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued Reference number: GID-TAG321

    Technology appraisal guidance
    Discontinued

  8. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued Reference number: GID-TAG330

    Technology appraisal guidance
    Discontinued

  9. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  10. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  11. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued Reference number: GID-TAG360

    Technology appraisal guidance
    Discontinued

  12. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued Reference number: GID-TAG363

    Technology appraisal guidance
    Discontinued

  13. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

    Technology appraisal guidance
    Discontinued

  14. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  15. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued Reference number: GID-TAG369

    Technology appraisal guidance
    Discontinued

  16. Venous leg ulcers - new treatments [ID394]

    Discontinued Reference number: GID-TAG370

    Technology appraisal guidance
    Discontinued

  17. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued Reference number: GID-TAG372

    Technology appraisal guidance
    Discontinued

  18. Prasterone for the treatment of systemic lupus erythematosus [ID392]

    Discontinued Reference number: GID-TAG373

    Technology appraisal guidance
    Discontinued

  19. Thrombophilia [ID393]

    Discontinued Reference number: GID-TAG374

    Technology appraisal guidance
    Discontinued

  20. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued Reference number: GID-TAG375

    Technology appraisal guidance
    Discontinued

  21. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  22. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  23. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  24. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  25. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  26. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  27. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  28. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  29. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  30. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued Reference number: GID-TAG389

    Technology appraisal guidance
    Discontinued

  32. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  33. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  34. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  35. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

    Technology appraisal guidance
    Discontinued

  36. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  37. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

    Technology appraisal guidance
    Discontinued

  38. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued

  39. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

    Technology appraisal guidance
    Discontinued

  40. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

    Technology appraisal guidance
    Discontinued

  41. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  42. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued

  43. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  44. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  45. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued Reference number: GID-TAG405

    Technology appraisal guidance
    Discontinued

  46. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development Reference number: GID-TAG406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued Reference number: GID-TAG407

    Technology appraisal guidance
    Discontinued

  48. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued Reference number: GID-TAG408

    Technology appraisal guidance
    Discontinued

  49. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued Reference number: GID-TAG411

    Technology appraisal guidance
    Discontinued

  50. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued